CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention.
Kayla R TunehagCameron D ThomasFrancesco FranchiJoseph S RossiEllen C KeeleyR David AndersonAmber L BeitelsheesJulio D DuarteYan GongRichard A KerenskyCaitrin W McDonoughAnh B NguyenLuis Ortega-PazSanjay VenkateshYehua WangJulie A JohnsonAlmut G WintersteinGeorge A StoufferDominick J AngiolilloLarisa H CavallariAnd Craig R LeePublished in: Journal of the American Heart Association (2024)
Black patients with CYP2C19 intermediate and poor metabolizer phenotypes who are treated with clopidogrel exhibit increased risk of adverse cardiovascular outcomes after PCI in a real-world clinical setting. Bleeding outcomes should be interpreted cautiously. Prospective studies are needed to determine whether genotype-guided use of prasugrel or ticagrelor in intermediate and poor metabolizers improves outcomes in Black patients undergoing PCI.
Keyphrases
- percutaneous coronary intervention
- acute coronary syndrome
- antiplatelet therapy
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute myocardial infarction
- coronary artery disease
- coronary artery bypass grafting
- atrial fibrillation
- patients undergoing
- coronary artery bypass
- emergency department
- heart failure
- adverse drug
- weight loss